Use of a pharmacokinetic model to assess chlorpyrifos exposure and dose in children, based on urinary biomarker measurements.
about
Nanotechnology-based electrochemical sensors for biomonitoring chemical exposuresUse of biomarkers to indicate exposure of children to organophosphate pesticides: implications for a longitudinal study of children's environmental healthUse of pharmacokinetic modeling to design studies for pathway-specific exposure model evaluation.Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurementsAnalysis of aggregate exposure to chlorpyrifos in the NHEXAS-Maryland investigation.The implications of using a physiologically based pharmacokinetic (PBPK) model for pesticide risk assessmentPhysicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment.Estimating absorbed dose of pesticides in a field setting using biomonitoring data and pharmacokinetic models.Reliability of urinary excretion rate adjustment in measurements of hippuric acid in urine.Biological monitoring of pesticide exposures in residents living near agricultural land.Reconstructing population exposures to environmental chemicals from biomarkers: challenges and opportunities.Evaluation of the U.S. EPA/OSWER preliminary remediation goal for perchlorate in groundwater: focus on exposure to nursing infants.Reconstructing organophosphorus pesticide doses using the reversed dosimetry approach in a simple physiologically-based pharmacokinetic modelCreatinine corrections for estimating children's and adult's pesticide intake doses in equilibrium with urinary pesticide and creatinine concentrations.Reconstructing human exposures using biomarkers and other "clues".Evaluation of predictive algorithms used for estimating potential postapplication, nondietary ingestion exposures to pesticides associated with children's hand-to-mouth behavior.Exposures of preschool children to chlorpyrifos and its degradation product 3,5,6-trichloro-2-pyridinol in their everyday environments.Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple biomarkers.The reliability of using urinary biomarkers to estimate children's exposures to chlorpyrifos and diazinon.Review of the Toxicology of Chlorpyrifos With an Emphasis on Human Exposure and NeurodevelopmentAgreement of pesticide biomarkers between morning void and 24-h urine samples from farmers and their children
P2860
Q23920102-6D64A6E5-480D-46BD-8BA3-4DB2BCE125E2Q24810438-84D4D7D6-A038-40C8-9C07-96AC9F0D66F5Q24810941-7CD964B6-D9F5-4D05-9CB4-9EB08278716FQ24814239-FF32F965-4FD3-4512-8A14-20BBB84DE382Q24815884-70049C70-2EE1-4F63-93FD-3CEEA73559CBQ28393965-3327179F-A89C-46E8-B113-DA9C7F7B8F06Q30925847-167138E5-E0DD-4572-8E74-27979A2167CFQ31145312-F8BB70EA-F86D-4F01-9DF5-3642A7B5AC3DQ33963812-B1A90CA5-3B0E-48BA-99B9-0F88B8A0AB59Q34072237-D4F99115-7829-4EFF-9164-A78B16BBFBAAQ34746222-BEFC984E-FC72-4211-814B-1B275BC4715AQ35745048-DC32E9A2-899E-4706-AEDD-E6C223E7D32FQ35837860-3A85512D-E9EF-4279-99C1-772B05FE5732Q36945544-F46AA0A0-932E-444D-9A96-CF90B7372E0CQ37971821-2B3B2478-EC10-4FDA-A902-2877AF9002D9Q38113292-2480329B-10F4-4CB0-8B34-BE202A722D60Q40482887-E76F2C03-E189-4898-9E66-B074D61ED017Q46609020-E2838165-6487-4CEA-B13D-A63F1B8368D5Q52705500-C8B5F848-D951-406E-BFF8-488D7138FAA2Q56432121-9B532449-2478-4207-93A0-B8EE1360D349Q58489725-E0A88294-4055-4030-AC32-8F6173E91478
P2860
Use of a pharmacokinetic model to assess chlorpyrifos exposure and dose in children, based on urinary biomarker measurements.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@en
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@nl
type
label
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@en
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@nl
prefLabel
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@en
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@nl
P2093
P356
P1476
Use of a pharmacokinetic model ...... rinary biomarker measurements.
@en
P2093
Quackenboss JJ
P304
P356
10.1093/TOXSCI/61.2.374
P577
2001-06-01T00:00:00Z